转移性前列腺癌是一种常见且致命的疾病。自[177Lu]Lu-PSMA-617获得批准以来，靶向放射性核素治疗（TRT）已成为一种现成的治疗选择。目前正在研究各种分子在前列腺癌中的 TRT。我们回顾了用于靶向前列腺癌细胞并优化药代动力学的同位素和载体的各种组合。有前景的创新包括改善生物分布的化学修饰、新靶点的识别以及α发射体等新型放射性同位素的使用。患者摘要：我们的小型综述总结了用于治疗转移性前列腺癌的靶向放射性药物的研究。几种有前途的放射性药物正在临床试验中进行评估，但在将它们用于常规临床实践之前还需要进行更多的研究。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [177Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. PATIENT SUMMARY: Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.